Hi Eaglenebula
Not sure I can provide any particular insight on this.
However, I would point out that in the potential pipeline shown in the presentation, glaucoma and LHON are listed as two examples of blinding eye diseases that might be treatable with PYC-001.
This suggests to me that these two indications haven’t been firmly decided; nor does it necessarily rule out acute ischemic optic neuropathy or other “blinding eye diseases where its mechanism of improving cellular bioenergetics holds potential for disease correction”.
Were the PYC-001 asset to be licensed out, I guess it would be the licensee’s call as to which indications would be pursued.
Hi Eaglenebula Not sure I can provide any particular insight on...
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
14.5¢ |
Change
0.015(11.5%) |
Mkt cap ! $676.5M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 14.5¢ | 12.5¢ | $663.7K | 4.832M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 135100 | 13.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.5¢ | 785480 | 9 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| PYC (ASX) Chart |